US-based manufacturer Capsugel has introduced its enTRinsic drug delivery technology platform.
enTRinsic offers provides full enteric protection and targeted release of gastric acid and heat-sensitive active ingredients to the upper gastrointestinal tract, without the need for functional coatings.
Go deeper with GlobalData
The technology allows oral delivery of a variety of compounds, including vaccines, proteins and peptides using pharmaceutically approved enteric polymers.
Capsugel Dosage Form Solutions president Amit Patel said: "Capsugel’s enTRinsic drug delivery technology is the result of our continued commitment to innovate for our customers.
"For years, the industry has been searching for a fully enteric dosage form that doesn’t require functional coatings.
"By leveraging Capsugel’s unique combination of formulation, polymer chemistry and manufacturing expertise, we have developed a novel solution for enteric protection and the targeted delivery of a wide range of sensitive molecules."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataenTRinsic is currently globally available for customer projects and follows the successful completion of an 18-month lead-user customer-collaboration programme that included feasibility studies with new and existing pharmaceutical products.
Capsugel Research and Development senior vice-president Keith Hutchison said: "Our lead-user programme confirmed the enteric performance of our enTRinsic technology in multiple applications, as well as the viability of the formulation and manufacture of finished drug product at scale.
"We are now excited to move beyond the lead-user programme and work with additional customers, while continuing to broaden the application of the technology to encompass gastric resistance, full enteric protection, and varied GI site targeting for an increasingly diverse range of APIs."
The enTRinsic technology further expands the company’s range of modified and targeted release solutions, as well as its biotherapeutic formulation offering.
The company noted that customers can access the technology platform through a services agreement at its locations in Ploërmel, France, and Bend, Ore.
In addition, enTRinsic can be tailored to specific customer projects and combined with other technologies, as warranted, to meet several target product profiles and commercial objectives.
